{"symbol":"REGN","fiscalQuarter":"Q2-2026","reportDate":"2026-07-30","reportTime":"BMO","status":"upcoming","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q2-2026","preBrief":{"companySnapshot":"Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for serious diseases. With a market cap of $74 billion, it plays a significant role in the health care sector, particularly in innovative treatments for conditions like cancer and eye diseases.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.","consensus":"N/A"},{"name":"Revenue Growth","why":"Revenue growth reflects the company's ability to expand its market presence and sales, crucial for long-term success.","consensus":"N/A"},{"name":"Product Pipeline Updates","why":"Updates on new drug developments can significantly influence investor sentiment and stock performance.","consensus":"N/A"}],"lastQuarterRecap":{"summary":"In Q1-2026, Regeneron reported an EPS of $9.47, exceeding estimates by 50.7%. However, the stock fell 6.21% the following day, indicating mixed market reactions despite strong earnings.","promises":[]},"wallStreetExpectations":{"summary":"Investors are cautiously optimistic ahead of the earnings report, given Regeneron's strong track record of beating EPS estimates. However, the lack of revenue guidance creates uncertainty.","bullCase":"If Regeneron continues its trend of beating EPS estimates, it could lead to significant stock appreciation, especially if there are positive updates on its product pipeline.","bearCase":"Conversely, if the company fails to meet expectations or provides disappointing updates on its drug pipeline, it could lead to a sharp decline in stock price."},"optionsSignal":{"impliedMove":"15.11%","context":"The options market is pricing in a significant potential move in either direction, reflecting uncertainty about the upcoming earnings report."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+50.70%","reaction":"-6.21%"},{"quarter":"Q4-2025","epsSurprise":"+38.18%","reaction":"-1.07%"},{"quarter":"Q3-2025","epsSurprise":"+57.31%","reaction":"+11.82%"},{"quarter":"Q2-2025","epsSurprise":"+94.45%","reaction":"+2.46%"},{"quarter":"Q1-2025","epsSurprise":"+24.32%","reaction":"-6.87%"},{"quarter":"Q4-2024","epsSurprise":"+25.51%","reaction":"+4.53%"},{"quarter":"Q3-2024","epsSurprise":"+23.89%","reaction":"-9.17%"},{"quarter":"Q2-2024","epsSurprise":"+29.47%","reaction":"+1.29%"}],"pivotalQuestions":[{"question":"What will be the EPS for Q2-2026?","whyItMatters":"Given Regeneron's history of beating EPS estimates, this number will be crucial for investor confidence and stock performance."},{"question":"Are there any updates on the product pipeline?","whyItMatters":"Investors are keen to know about any advancements or setbacks in Regeneron's drug development, as this can significantly impact future revenue."}],"thesisBreakLevels":{"bullTrigger":"A reported EPS of $10 or higher would confirm the bull case and likely lead to a positive market reaction.","bearTrigger":"An EPS below $8 would confirm the bear case and could result in a significant stock decline.","context":"The market is debating whether Regeneron can maintain its strong earnings performance amidst uncertainties in its product pipeline."},"scenarioPlaybook":{"beatAndRaise":"If Regeneron beats expectations, history suggests the stock could rise by around 1.01% on average, confirming strong operational performance.","inLineCautious":"If results are in line with expectations, the stock may see muted movement as investors await further clarity on future guidance.","miss":"Should the company miss expectations, history suggests a potential decline of around 0.40% on average, reflecting investor disappointment."},"whatTheStreetIsMissing":{"thesis":"The Street may be underestimating the impact of Regeneron's robust product pipeline, which could lead to stronger-than-expected revenue growth despite current uncertainties.","supportingPoints":["Regeneron has consistently beaten EPS estimates, indicating strong operational execution.","The options market is pricing a significant move, suggesting that investors are anticipating volatility that may not align with actual performance."],"riskToConsensus":"If the product pipeline shows promising advancements, it could lead to a reevaluation of growth expectations."},"whatToListenFor":["Any updates on the progress of new drug candidates in the pipeline.","Management's outlook on revenue growth for the upcoming quarters.","Details on any regulatory approvals or setbacks.","Insights into market demand for existing products.","Commentary on competitive pressures in the biotechnology sector."],"metaDescription":"Regeneron (REGN) reports Q2 2026 earnings July 30. Investors are watching for EPS and product pipeline updates."}}